UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 20-5093315 (I.R.S. Employer Identification No.) 343 Alle ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q2 2022 Earnings Conference Call November 10, 2021 5:00 PM ET Company Participants Mark Flather – Vice President of Investor Relations Shawn Singh – Chief Executive Officer Jerry Dotson – Chief Financial Officer Mark Smith – Chief Medical Officer Conference Call Participants Brian Skorney – Robert W. Baird Tim Lugo – William Blair Jason McCarthy – Maxim Group Andrew Tsai – Jefferies Operator Greetings, and welcome to VistaGen Therapeutic Second Quarter of Fiscal Yea ...

Form 10-Q ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2022 Earnings Conference Call August 12, 2021 5:00 PM ET Company Participants Mark Flather - Vice President, Investor Relations Shawn Singh - Chief Executive Officer Jerry Dotson - Chief Financial Officer Mark Smith - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Operator Greetings, and welcome to the VistaGen Therapeutics First Quarter 2022 Results Conference Call. During the presentation, all participants will be in a listen-only m ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) Indicate by check mark whether the regi ...

A VISIONARY APPROACH TO MENTAL HEALTH CARE | --- | --- | |-------|-------| | | | | | | COMPANY HIGHLIGHTS • Three innovative CNS drug candidates advancing in clinical development • Unique mechanisms of action • Therapeutic potential in multiple anxiety, depression and neurology markets • Lead candidate in NDA-enabling Phase 3 development for acute treatment of anxiety in adults with Social Anxiety Disorder • FDA Fast Track Designation in Social Anxiety Disorder, Major Depressive Disorder and Neuropathic Pai ...

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q4 2021 Earnings Conference Call June 29, 2021 5:00 PM ET Company Participants Mark Flather - Vice President of Investor Relations Shawn Singh - Chief Executive Officer Jerrold Dotson - Vice President, Chief Financial Officer and Secretary Mark Smith - Chief Medical Officer Conference Call Participants Tim Lugo - William Blair Brian Skorney - Robert W. Baird Andrew Tsai - Jefferies Jason McCarthy - Maxim Group Operator Greetings. Welcome to VistaGen Therapeutics F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended: March 31, 2021 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commission file number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Nevada 20-5093315 (I.R.S. E ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of inc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-37761 VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of in ...